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Leptin, the gene product of adipose tissue that sig-
nals caloric plentitude via central nervous system
receptors, may also have diverse peripheral meta-
bolic actions. Of paramount interest has been the
potential interaction(s) between leptin and insulin.
Insofar as insulin alters leptin secretion/action (or
vice versa), dysregulation of this system could con-
tribute to disease states such as diabetes.
The purpose of this study was to examine the
effect of exogenous insulin on serum leptin in
children with newly-diagnosed Type 1 diabetes.
Since these patients are hypoinsulinemic (insulin-
deplet.ed) at diagnosis, they present an ideal
opportunity to examine the effect of insulin reple-
tion on serum leptin. Seventeen patients were
enrolled. At baseline (prior to insulin therapy),
leptin levels were 4.3 +_. 1.1ng/ml; they were not sta-
tistically related to the baseline serum insulin or
illness severity. There was no significant change in
serum leptin before, shortly (1-6 days) or several
weeks (3-26 weeks) after insulin treatment even
when the data was corrected for changes in BMI,
hemoglobin Alc, and daily insulin dose. Since
repletion of the insulin deficiency that is present
in non-acidotic, ambulatory patients with new
onset Type 1 diabetes did not alter serum leptin,
these results argue against an effect of insulin on
serum leptin in the absence of the acute diabetic
ketoacidosis. Because as the recuperative months
following the diagnosis of new onset Type 1
diabetes are marked by weight gain, the absence
of a rise in serum leptin might also indicate
either an adaptive (weight permissive) or patho-
logic (impaired secretory) deficit.
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INTRODUCTION
Leptin, the product of the obese (ob) gene, is a
16kd peptide which is produced primarily by
adipose tissueIll although it is now evident that
the gene is also transcribed in stomach and
placenta. I21 Although leptin’s precise role in
humans is unsettled, in rodents the hormone
controls body weight and energy expenditure
through feedback signaling via hypothalamic
receptors.TM In all normal mammals studied to
date, the plasma concentration of leptin strong-
ly correlates with percent body fat. I41 Addition-
ally, in humans, there is a gender effect in so far
as females tend to have higher plasma levels
even after adjusting for body fat. I5’61 The
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predominant hormones which are felt to gov-
ern leptin ob mRNA and plasma concentra-
tions, both in vivo and in vitro, are
glucocorticoids and insulin.[7-1,111 Of these two,
from a teleological standpoint, insulin is the
choice of most to be the preeminent physiologi-
cal regulator and would account for the
enhanced production of leptin in adipocytes
which accompanies an increase in caloric
intake. A correlation between serum leptin and
insulin can be found,I121 even after normalizing
the data for percent body fat. Previous studies
have found that either acute insulin treatment
in lean rats or food ingestion increases ob gene
expression and/or serum leptin levels.I31 In
humans, a 1996 study found that supra physio-
logic hyperinsulinemia increases leptin levels
after only 4 hours. [14] However, antithetically,
several reports have not been able to show that
acute exposure to insulin regulates leptin lev-
els. For instance, in two separate studies in
humans, no effect of exogenous insulin on
serum leptin levels was observed unless hyper-
insulinemia persisted for 24 hours or more. [15’16]
In fact, we [171 and others [ls-2l have evidence
that in the presence of steroids, insulin actually
attenuates leptin secretion in either cultured
adipocytes or adipose tissue.
To further define the relationship between
serum leptin and insulin dynamics, we studied
children with new-onset Type 1 diabetes who
were managed in an outpatient care program.
They provide a prime opportunity to examine
the impact of exogenous insulin on circulating
leptin levels in humans with profound
hypoinsulinism. Our study is unique in that the
children studied were largely nonketotic as
determined by serum bicarbonate (only 3 of 17
were admitted for intravenous treatment of
mild ketoacidosis). Since nearly all Type 1 dia-
betics demonstrate significant weight gain after
insulin treatment,I211 this fact alone, regardless
of the aforementioned direct effects of insulin
per se on leptin synthesis, should lead to an
increase in serum leptin. We prospectively
followed serum leptin concentrations in 17
untreated new onset diabetics from baseline
(prior to insulin therapy) through two succes-
sive follow-up clinic visits.
METHODS
Subjects
Informed consent was obtained from the parents
and patients prior to enrollment. The study was
approved by the Institutional Review Board. All
untreated Type 1 new-onset diabetic children
referred to the endocrine unit were asked to par-
ticipate. Patients were excluded from the study
for the following reasons: abnormal thyroid
function or antibodies, previous history of
chronic disease, prior insulin therapy, history of
any concurrent drug treatment or the develop-
ment of an intercurrent illness during the study
period. The study group comprised 17 untreated
Type 1 diabetics (7 males/10 females, mean age
8.6yrs + 4.9 (range 2.6-17.2), mean blood glu-
cose (mM) 23.1 11.2 (range 13.4-53.1)). Only 3
required brief hospitalization for intravenous
hydration and mild ketoacidosis, defined as a
serum total CO2 below 17mM.
Parenteral fluids (3 of 17 patients), if necessary,
and insulin requirements and adjustments were
under the supervision of the endocrinology
service. Upon recruitment (baseline), detailed in-
formation was obtained regarding duration of
symptoms, weight loss (if available), history of
vomiting, or history of anorexia or polyphagia
for the 24hrs preceding insulin treatment.
Heights and weights were obtained at baseline
and at both subsequent follow-up visits. The first
follow-up visit was shortly after diagnosis (range
1-6days) and the other several weeks thereafter
(range 2.9-25.9 weeks; mean 18.2+ 6.0SD). At
the latter appointment, the mean daily dose of
insulin per kg body weight was recorded.
Assays
As to blood studies, at baseline (prior to
insulin treatment) the following were mea-
sured: venous pH, electrolytes, total CO2,
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BUN, creatinine, glucose, insulin, hemoglobin
Alc(HbAlc), and, of course, leptin. Blood leptin
and glucose were analyzed at both follow-up
visits (herein referred to as the first and second
return visits) while HbAlc was measured a
baseline and the second follow-up visit.
Serum leptin concentrations were measured in
triplicate by radioimmunoassay (RIA) using a
commercially available kit (Linco Research, St.
Charles, MO) with a limit of sensitivity of
0.5ng/ml. The intra assay coefficient of varia-
tion was 7.1% at 10ng/ml and the respective
between-assay coefficient was 6.8%. During the
course of the study each subject had 3 separate
leptin measurements (baseline plus 2 follow-
up visits) and these were batched together
in the same assay. Prior to measurment, sera
was stored at-70C. HbAc was measured
by immunoassay with a nondiabetic range
4.2-6.2% (DCA 2000TM Analyzer, Miles Inc.,
Tarrytown, NY). Immunoreactive human insulin
was measured by a commercially available assay
(Diagnostic Products Corp., Los Angeles, CA).
At 15U/ml insulin the respective intra- and
interassay coefficients of variation were 6.9%
and 8.9%. Routine chemistries (venous pH,
electrolytes, total CO2, BUN, creatinine) were
obtained through the hospital clinical lab.
Statistics
Statistical comparisons were done by Students
t-test and regression analysis. The potential
effect of variables such as the clinical severity at
presentation, insulin dose, the percent change in
HbAic and the % change in BMI were tested
using the analysis of variance (ANOVA). All
values are expressed as the mean + SD.
RESULTS
Leptin and Insulin Levels at Baseline
The mean serum leptin level, insulin, HbAc,
and body mass indices are shown in Table I.
There was no statistical relation between
TABLE Patient characteristics and blood values at the
baseline and final follow-up visits
Bseline Final visit"
Body mass index 15.5 1.8 16.9 2.0
Weight (kg) 26.8 11.8 30 11.0
Leptin (ng/ml) 4.3 1.1 5.1 3.5
HbAlc 10.9 __+ 1.6 8.6 1.1
Insulin (U/ml) 3.7 3.6
Data are presented as mean SD on the 17 enrolled patients
at baseline (before insulin therapy) and at their final (or sec-
ond return) visit as per methods.
the baseline serum insulin and leptin concen-
trations. Moreover, baseline leptin levels were
not statistically related to the presence or
severity diabetes symptoms at presentation
(duration of symptoms, history of vomiting, %
weight loss, or history of either polyphagia or
anorexia).
Serum Leptin: Response to Insulin
Therapy
The temporal changes in serum leptin concen-
tration in each of the 17 patients are shown in
Figure 1. The mean serum leptin level (ng/ml)
at the first and second return visits were 4.2 +
1.0 and 5.1 +3.3ng/ml. These follow-up leptin
concentrations were not statistically different
from the basal leptin. The serum leptin levels of
the three children who presented with mild
ketoacidosis and, therefore, received intra-
venous fluids and insulin, were examined
separately to determine if leptin levels might
change during the course of DKA therapy in
these patients. The temporal change in serum
leptin was not significant: the mean concentra-
tions were 4.7+1.0 (at baseline), 4.4+1.0 (at
0.3-0.4 weeks) and 5.3_3.1ng/ml (at 9.5-26
weeks).
All of the patients gained weight after
insulin treatment (Tab. I). There was no corre-
lation (p > .05) between the % changes in BMI
(as measured at the 2nd return visit) and
the % changes in serum leptin (Fig. 2).
With the exception of 2 patients, the diabetic
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FIGURE 1 Temporal change in serum leptin. The temporal changes in serum leptin for the 17 study patients are shown. Blood
samples were obtained and measured per methods.
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FIGURE 2 Comparison between the percent changes in serum leptin and body mass index (BMI) in children with newly
IDDM during their initial three months of insulin therapy. Correlation between the percent change in serum leptin and the per-
cent change in BMI in the 17 study patients. Data was analyzed by linear regression; no statistically significant relationship was
evident.
children had a reduction in HbAlc values
between baseline and the final examination
(Tab. I). Nevertheless, when the individual per-
cent changes in HbAlc were plotted against the
percent change in serum leptin, there was no
significant correlation (data not included).
Finally, the patient’s daily dose of insulin per
kg body weight at the final visit did not corre-
late with their percent change in serum leptin
(not shown).
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DISCUSSION
The primary goal of this study was to determine
whether serum leptin would change over the
first few months of insulin replacement therapy
in children with newly diagnosed Type 1 dia-
betes. The study population was composed of 17
patients 14 of which were entirely managed as
outpatients in an clinic program for newly diag-
nosed patients. We reasoned that if leptin is reg-
ulated by insulin, then serum leptin should
change (increase) during the transition from the
hypoinsulinemia that characterizes new onset
Type 1 diabetes at presentation to full insulin
replacement over the ensuing months. More-
over, since weight gain is usual during this same
period, that in itself should increase leptin. Con-
trary to our hypothesis, we found no significant
change in leptin despite resolution of hyper-
glycemia, increased weight and statistical cor-
rection for potential confounding variables.
Studies examining the direct effects of
insulin on blood leptin levels have largely sup-
ported a positive correlation between the two
hormones. The majority of in vivo studies have
shown (both in clinically well, non-diabetic
individuals and patients with either Type 1 or
Type 2 diabetes) that 3-6 hours of euglycemic
hyperinsulinemia increases serum leptin by
approximately 50O/o. [14’22-25] Analogously, serum
leptin is elevated in patients with insulinoma
but normalizes after tumor resection. I261 Dis-
cordant with this, two studies found no change
in serum leptin after 5 hours of euglycemic
hyperinsulinemia in either normal or diabetic
subjects.[12,15]
In adult nonobese men with well-controlled
Type 1 diabetes, fasting serum leptin levels were
over twice non-diabetic levels but did not corre-
late with fasting insulin levels. In this same
study, four hours of euglycemic hyperinsuline-
mia increased serum leptin by 25% in controls
but not in the subjects with diabetes. I221 Healthy,
lean prepubertal children with stable Type I also
have higher fasting serum leptin levels relative
to controls, an association which could be due to
insulin therapy. [27]
A molecular mechanism has been proposed to
explain how insulin and nutritional signals might
regulate serum leptin. The candidate transcrip-
tion factor, adipocyte determination differentia-
tion dependent factor 1/sterol regulatory element
binding protein I (ADD1/SREBP1)I which is acti-
vated by insulin and prior feeding causes
increased leptin secretion and ob mRNA in fat tis-
sue. [26] Despite this, however, in vitro studies of
cultured fat tissue and cells have yielded oppos-
ing results concerning the sustained effect of
insulin on leptin secretion.[18,19’ 28’ 291
Several recent studies have addressed the effect
of acute insulin therapy in insulin deficient dia-
betes (either newly diagnosed patients with Type
I diabetes in ketoacidosis or ketosis[3,3] or insulin
withdrawal. I32] In a study of 19 newly diagnosed
children with Type 1 diabetes who presented in
ketosis and/or ketoacidosis leptin levels were 46%
reduced (compared to controls) just prior to
insulin treatment,t3l These depressed leptin levels
corrected to 66 and 77% of normal after I and 3-5
days, respectively, commensurate with intensive
(every 4-6 hours) insulin administration for the
first 24 hours of therapy followed by conventional
twice daily insulin thereafter. Our results differ in
that we detected no change in serum leptin over a
similar observation period. These contrasting
results could be due to differences in the degree of
illness severity between patient cohorts. Upon
entrance into the aforementioned study,[3] 15/19
of the patients were in ketosis and/or ketoaci-
dosis, however, specific acid-base measurements
were not provided. In contrast, only 3/17 of our
patients were in mild ketoacidosis as defined by a
serum bicarbonate < 17mM. We did not enroll a
control group since the purpose of this study was
to prospectively follow the change in serum leptin
during the transition from a state of hypoinsuline-
mia to one of insulin repletion. With this study
design, patients served as their own controls. Evi-
dence corroborating the positive change in insulin
status in this cohort was the increase in BMI
(all patients) and reduction in Hbalc (all but
2 patients). Furthermore, it is well recognized
that new-onset patients with Type 1 diabetes
and classic symptoms (polydipsia, polyuria) are
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hypoinsulinemic at diagnosis and that conven-
tional insulin therapy exposes tissues to supra-
physiologic concentrations o[ insulin.[331 In another
studyo sick children with diabetic ketoacidosis [31]
serum leptin were also about 50% decreased at
presentation and normalized rapidly with 24
hours o intensive insulin and fluid therapy. Of
interest, in a subset o these patients who were
well enough to eat, there was a less dramatic rise
in leptin over the study period. It would be of
interest to know i[ these patients were less acidotic
on presentation. This study differs rom ours in
that it exclusively examines the first 24 hours o
treatment o acute diabetic ketoacidosis. We avoid
the potential biochemical, hormonal and fluid and
electrolyte variables associated with ketoacidosis
by studying clinically well patients and ollowing
them for several months.
Several observations are noteworthy regard-
ing the potential impact o the insulin deficient
state on serum leptin. Firstly, while the observed
changes in serum leptin that occur during the
initial insulin therapy in patients with new onset
diabetes could be due to the insulin per se, the
correction o other concomitant abnormalities in
the metabolic and hormonal milieu might also
affect serum leptin. Along these lines, insulin
deficiency might be associated with changes in
serum protein binding and/or the binding o
leptin in peripheral pools with subsequent
enhancement of leptin clearance.[34-361 The
importance o leptin clearance over leptin pro-
duction in determining ambient serum leptin
has been proven. [35,37,38] Moreover, even free
fatty acids, which increase with insulin deficien-
cy, bind to leptin and could potentially effect
leptin clearance. [391 Catecholamines, which sup-
press leptin, might also have a role in lowering
leptin levels in new diagnosed Type 1 diabetic
patients. In summary, since the metabolic/hor-
monal milieu may vary with illness severity,
these attendant factors could, in part, explain the
disparate results (both in human and rodent
data) regarding the action of insulin repletion on
serum leptin in insulin-deficient diabetes.
Our study is unique in that it examines a cohort
of children with mild non-acidotic, new onset
Type 1 diabetes. Given that the patients were not
direly ill, the impact of hypoinsulinemia and sub-
sequent insulin repletion on serum leptin could be
prospectively examined independent of ketoaci-
dosis (only three patients had serum bicarbonate
less than 17mM). This is corroborated by data
demonstrating the absence of a statistical relation-
ship between either the baseline leptin and the
percent change in leptin, baseline insulin levels, or
changes in weight, BMI or HbAlc. Also, the
absence of an effect of insulin replacement on lep-
tin levels in our patients cannot be due to inade-
quate insulin repletion since all patients had a
rapid resolution of symptomatic hyperglycemia
and all had an increase in BMI and reduction
HbAlc (15/17 patients). Notwithstanding the
increase in body weight over the observation peri-
od, there was still no significant change in serum
leptin despite up to 3 months of insulin replace-
ment. Our results demonstrate that in the non-
ketotic, insulin-deficient state of clinically stable
new onset Type 1 diabetes, insulin replacement
therapy does not affect serum leptin despite
improved glycemic control and weight gain.
Given that our data did not show increased leptin
with weight gain a possible corollary to these
observations may be that patients with Type I dia-
betes have a relative deficiency (adaptive or
disease-related) in leptin secretion in this initial
post diagnosis time period.
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